New and old antipsychotics: what 'effectiveness' trials tell us

Psychiatry

Volumn 7, Issue 11, 2008, Pages 443-446

  Michalopoulou, Panayiota G ^a,b   Shergill, Sukhwinder S ^a,b   Kapur, Shitij ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

antipsychotics; clozapine; first generation antipsychotics; schizophrenia; second generation antipsychotics

Indexed keywords

AMISULPRIDE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL RESEARCH; CLINICAL TRIAL; COGNITION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; HUMAN; METABOLIC DISORDER; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SATISFACTION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 55249116550     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mppsy.2008.08.006     Document Type: Review

References (34)

1. Leucht S., Arbter D., Engel R.R., Kissling W., and Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 13 (2008) 1-19
2. Prien R.F., and Cole J.O. High dose chlorpromazine therapy in chronic schizophrenia. Report of National Institute of Mental Health - psychopharmacology research branch collaborative study group. Arch Gen Psychiatry 18 (1968) 482-495
3. Gilbert P.L., Harris M.J., McAdams L.A., and Jeste D.V. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry 52 (1995) 173-188
4. Lewis D.A., and Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron 28 (2000) 325-334
5. Miyamoto S., Duncan G.E., Marx C.E., and Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10 (2004) 79-104
6. Goldberg S.C. Negative and deficit symptoms in schizophrenia do respond to neuroleptics. Schizophr Bull 11 (1985) 453-456
7. Leucht S., Pitschel-Walz G., Abraham D., and Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 35 (1999) 51-68
8. Cleghorn J.M., Kaplan R.D., Szechtman B., Szechtman H., and Brown G.M. Neuroleptic drug effects on cognitive function in schizophrenia. Schizophr Res 3 (1990) 211-219
9. Sweeney J.A., Haas G.L., Keilp J.G., and Long M. Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year followup study. Psychiatry Res 38 (1991) 63-76
10. Mishara A.L., and Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 55 (2004) 1013-1022
11. Siris S.G. Depression in schizophrenia: perspective in the era of 'atypical' antipsychotic agents. Am J Psychiatry 157 (2000) 1379-1389
12. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 (1988) 789-796
13. Wahlbeck K., Cheine M., Essali A., and Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 156 (1999) 990-999
14. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 (1999) 233-256
15. Meltzer H.Y., and Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 152 (1995) 183-190
16. Walker A.M., Lanza L.L., Arellano F., and Rothman K.J. Mortality in current and former users of clozapine. Epidemiology 8 (1997) 671-677
17. Spivak B., Shabash E., Sheitman B., Weizman A., and Mester R. The effects of clozapine versus haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry 64 (2003) 755-760
18. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
19. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60 (2003) 553-564
20. Adams C.E., Coutinho E., Duggan L., Gilbody S., Leucht S., and Wahlbeck K. Cochrane schizophrenia group. Cochrane Database Syst Rev 4 (2003) CDD51334
21. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., and Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 159 (2002) 561-566
22. Lindenmayer J.-P., Czobor P., Volavka J., et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160 (2003) 290-296
23. Heres S., Davis J., Maino K., Jetzinger E., Kissling W., and Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry 163 (2006) 185-194
24. National Institute for Health and Clinical Excellence. NICE implementation uptake report: atypical antipsychotic drugs for the treatment of schizophrenia (2008), NICE, London
25. Zerhouni E. Medicine. The NIH Roadmap. Science 302 (2003) 63-72
26. Flay B.R. Efficacy and effectiveness trials (and other phases of research) in the development of health promotion programs. Prev Med 15 (1986) 451-474
27. March J.S., Silva S.G., Compton S., Shapiro M., Califf R., and Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry 162 (2005) 836-846
28. Rosenheck R.A., Leslie D.L., Sindelar J., et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163 (2006) 2080-2089
29. Keefe R.S.E., Bilder R.M., Davis S.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64 (2007) 633-647
30. McEvoy J.P., Lieberman J.A., Stroup T.S., et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163 (2006) 600-610
31. Jones P.B., Barnes T.R.E., Davies L., et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63 (2006) 1079-1087
32. Lewis S.W., Barnes T.R.E., Davies L., et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32 (2006) 715-723
33. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
34. Kahn R.S., Fleischhacker W.W., Boter H., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371 (2008) 1085-1097